South America Travel Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Hepatitis A, Hepatitis B, Meningococcal Vaccines, and Others) and Application (Domestic Travel and Outbound Travel)

The travel vaccines market in SAM is expected to grow from US$ 143.20 million in 2021 to US$ 243.85 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2021 to 2028.

The SAM travel vaccines market is segmented into  Brazil, Argentina, and the Rest of SAM. During the forecast period, the region is expected to continue its dominance due to an increase in the prevalence of regional diseases, rapid technological innovations, vaccine development, and an increasing geriatric population. Brazil is the major vaccine manufacturer in the region. The country is self-sufficient for 54% of vaccination needs, including DTP, DT for adults and infants, TT, HepB, and DTP combined vaccines (DTP-HB and DTP-HB-Hib), seasonal influenza vaccine, YF vaccine, and meningo AþC. Brazil is one of the major worldwide producers of the YF vaccine, with the lowest market price. Similar to Brazil, Argentina is also the largest country in the region. Argentina has an upper middle-income economy with a diversified industrial sector. The country’s GDP was US$ 123,369 million in 2021. The GDP of Argentina has grown at a compound rate of 6.8% over the last five years. Major countries contributing to the market's growth include Chile, Colombia, Peru, Cuba, Venezuela, and Bolivia. The countries offer significant growth opportunities for the growth of the market. The factors such as increasing focus on vaccine research, continuous advancements in vaccine development technologies, and increasing government spending on pharmaceutical R&D in the region are expected to boost the travel vaccines market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the SAM travel vaccines market. The SAM travel vaccines market is expected to grow at a good CAGR during the forecast period.     

 SAM Travel Vaccines Market Revenue and Forecast to 2028 (US$ Million)

SAM Travel Vaccines Market Segmentation              

SAM travel vaccines market is segmented into product, application, and country. The SAM travel vaccines market, based on product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. In 2021, the others segment held the largest share of the market. The SAM travel vaccines market, based on application, is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment held the largest share of the market. Based on country, the SAM travel vaccines market is segmented into Brazil, Argentina, and the Rest of SAM.    

Abbott; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; and Sanofi are among the leading companies in the travel vaccines market in the region.

1. Abbott
2. GlaxoSmithKline plc
3. Merck & Co., Inc.
4. Novartis AG
5. Pfizer Inc.
6. Sanofi

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the SAM travel vaccines market
• Highlights key business priorities in order to assist companies to realign their business strategies 
• The key findings and recommendations highlight crucial progressive industry trends in the SAM travel vaccines market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the travel vaccines market, as well as those hindering it 
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution